Liquidia schedules first commercial shipment of YUTREPIA

Liquidia (LQDA) announced that Liquidia is scheduled to make its first commercial shipment of YUTREPIA inhalation powder, marking the first time YUTREPIA will be available to be prescribed to patients at specialty pharmacies. This milestone was achieved only five business days following the U.S. FDA approval of YUTREPIA on May 23, 2025, for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. On May 30, 2025, the U.S. District Court for the Middle District of North Carolina denied United Therapeutics’ (UTHR) request for a preliminary injunction and a temporary restraining order in its complaint filed against Liquidia (Case No. 1:25-cv-00368) alleging infringement of U.S. Patent No. 11,357,782 (the ‘782 patent). UTHR sought to enjoin Liquidia from commercializing YUTREPIA for the treatment of patients with PAH and PH-ILD. The Court denied the request, in part, based on its conclusion that UTHR is not likely to succeed on the merits of its claims. Liquidia has also filed a motion to dismiss, stay or transfer UTHR’s claims regarding the ‘782 patent. That motion remains pending with the Court. With this denial, UTHR no longer has any motions pending that seek emergency relief to enjoin the launch of YUTREPIA.